3
Announcements
Trials
Browse
Landscape
Status
Completed
4
Unknown
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
47
Carcinoma, Hepatocellular
9
Triple Negative Breast Neoplasms
7
Stomach Neoplasms
6
Inflammatory Breast Neoplasms
6
Lymphoma, Large B-Cell, Diffuse
4
Urinary Bladder Neoplasms
3
Non-Muscle Invasive Bladder Neoplasms
3
Esophageal Neoplasms
3
Recurrence
2
Lymphoma
2
Breast Neoplasms, Male
2
Breast Diseases
2
Upper Tract Urothelial Carcinoma
1
Thymoma
1
Small Cell Lung Cancer Extensive Stage
1
Sarcoma
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Postoperative Complications
1
Pancreatic Neoplasms
1
Oesophagogastric Cancer
1
Neoplastic Cells, Circulating
1
Neoplasms, Unknown Primary
1
Neoplasms
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell
1
Lung Neoplasms
1
Liver Neoplasms
1
Leiomyosarcoma
1
Interventions
Sorafenib
9
Radiofrequency Ablation
7
Oxaliplatin
7
Fluorouracil
6
Doxorubicin
6
Neoadjuvant Therapy
5
toripalimab
4
lenvatinib
4
Injections
4
Chemotherapy, Adjuvant
4
Bevacizumab
4
sintilimab
3
pembrolizumab
3
Ultrasonography
3
Thalidomide
3
Leucovorin
3
Irinotecan
3
Cisplatin
3
tislelizumab
2
durvalumab
2
camrelizumab
2
anlotinib
2
Walking Speed
2
Standard of Care
2
Radiosurgery
2
Oncolytic Virotherapy
2
Metformin
2
Liver Transplantation
2
Laparoscopy
2
Immunohistochemistry
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Liver Neoplasms
×
Epirubicin
×
Clear all
NCT03668418
2018-09-12
xenoZ
University of Pisa
Unknown
120 enrolled